Budesonide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Budesonide: From Corticosteroid Anti-Inflammatory Therapy to Atopic Eczema
One-Sentence Summary
Budesonide is a glucocorticoid whose original approved indication is not documented in this evidence pack (no Norway marketing authorizations on record), but it is broadly known as a corticosteroid used for chronic inflammatory conditions of the airway and gastrointestinal mucosa. The TxGNN model predicts it may be effective for Atopic Eczema (Atopic Dermatitis), with 2 clinical trials (both only tangentially related) and 20 publications currently associated with this direction, most of which address contact sensitization, pediatric safety, or early-stage formulation work rather than direct efficacy trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — Budesonide has no Norway marketing authorizations on record (0 licenses); no approved indication text in evidence pack |
| Predicted New Indication | Atopic Eczema (Atopic Dermatitis) |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L4 |
| Norway Market Status | Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold (Research Question stage) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for budesonide as a standalone entry in this evidence pack (flagged as a High-severity data gap). Based on the model's own repurposing rationale, budesonide is a potent glucocorticoid that inhibits the NF-κB pathway and suppresses pro-inflammatory cytokine release. When applied locally, this reduces epidermal inflammation and barrier dysfunction — the same class-effect mechanism by which topical corticosteroids are used to treat atopic dermatitis.
However, budesonide is not typically a first-line topical agent for atopic eczema (hydrocortisone and mometasone are more commonly used in that role), and the evidence pack itself notes that direct clinical evidence for budesonide specifically in AD treatment is limited. The supporting literature largely covers adjacent topics — allergic/contact sensitization patterns in AD patients, pediatric safety of topical glucocorticoids (growth and bone turnover effects), and a single preclinical nanoparticle-hydrogel formulation study — rather than controlled efficacy trials of budesonide against AD.
Mechanistically, the prediction is plausible as a corticosteroid class effect (anti-inflammatory action on epithelial/mucosal barriers), consistent with budesonide's established broader use across mucosal inflammatory diseases (e.g., respiratory and GI tract, per the literature captured in this pack). But since budesonide's own approved-indication profile and MOA data are not documented here, and no dedicated RCT of budesonide for AD exists in the current evidence, this remains a research hypothesis rather than a validated repurposing signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04680117 | N/A | Unknown | 150 | Characterizes severe pediatric asthma endotypes (immune, metabolomic, microbial features); atopy is a secondary phenotype variable, not a treatment endpoint for eczema (relevance grade C). |
| NCT01028560 | Phase 1/2 | Completed | 58 | Evaluates allergy immunotherapy to prevent asthma morbidity in atopic, wheezing children; eczema/food allergy noted as comorbid risk factors, not a direct budesonide-AD efficacy trial (relevance grade C). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38275852 | 2024 | Preclinical formulation study | Gels (Basel) | pH-sensitive budesonide nanoparticle hydrogel developed for local delivery in pediatric atopic dermatitis; addresses dermal-absorption and side-effect limitations. |
| 21062310 | 2010 | RCT (veterinary) | J Vet Pharmacol Ther | Randomized, blinded, placebo-controlled trial of topical 0.025% budesonide conditioner in canine atopic dermatitis; reduced skin lesions/pruritus and improved quality of life. |
| 35133669 | 2022 | Cohort | Contact Dermatitis | Compares contact sensitization patterns between AD and non-AD patients in an Asian dermatology cohort. |
| 19875223 | 2010 | Cohort | Allergologia et Immunopathologia | Assesses budesonide response among atopic vs. non-atopic infants/preschoolers with recurrent wheezing. |
| 30053491 | 2018 | Cohort | J Am Acad Dermatol | Examines allergic contact dermatitis to topical medications and personal care products in adults with AD. |
| 9496795 | 1998 | Cohort/interventional | Pediatric Dermatology | Knemometry study assessing short-term growth effects of topical budesonide in children with AD. |
| 8864369 | 1996 | Cohort/interventional | Dermatology (Basel) | Evaluates IGF axis, bone, and collagen turnover in children with AD treated with topical glucocorticosteroids. |
| 33931866 | 2021 | Cohort | Contact Dermatitis | SIDAPA baseline patch-test series (Italy) reporting trends in budesonide contact allergy. |
| 24603519 | 2014 | Cohort | Dermatitis | Contact hypersensitivity to standard-series and corticosteroid-series haptens in adolescents/adults with AD. |
| 19571596 | 2009 | Review | Neuroimmunomodulation | Reviews adrenal suppression risk from intranasal corticosteroids in patients with coexisting allergic rhinitis/asthma/AD. |
Norway Market Information
Currently no marketing authorization records are available — Budesonide is not marketed in Norway per this evidence pack (0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are not available in this evidence pack — TFDA/regulatory label data is flagged as a Blocking-severity gap, DG001.)
Conclusion and Next Steps
Decision: Hold (Research Question stage)
Rationale: The corticosteroid anti-inflammatory mechanism is biologically plausible for atopic eczema, but the current evidence for budesonide specifically consists of only 2 indirectly related clinical trials (relevance grade C) and literature dominated by contact-sensitization epidemiology, pediatric safety studies, and a single preclinical formulation paper — not controlled efficacy trials. This corresponds to L4 evidence (mechanism/preclinical only), insufficient to move beyond a research question.
To proceed, the following is needed:
- Drug's own MOA data via DrugBank API (DG002, High severity)
- TFDA/regulatory package insert — warnings and contraindications (DG001, Blocking severity; required before any S1 safety pre-assessment)
- A dedicated clinical trial (RCT) testing topical budesonide efficacy against atopic dermatitis, since none currently exists
- Route/formulation compatibility assessment (topical vs. existing inhaled/oral/rectal budesonide formulations)
- Note: the pack's #2-ranked prediction, bronchitis, carries stronger L2 evidence with a "Proceed with Guardrails" recommendation and may warrant separate evaluation in parallel
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.